Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe | Zendy

Andrea De Luca | Zendy; David Dunn | Zendy; Maurizio Zazzi | Zendy; Ricardo Camacho | Zendy; Carlo Torti | Zendy; Iuri Fanti | Zendy; Rolf Kaiser | Zendy; Anders Sönnerborg | Zendy; Francisco M. Codoñer | Zendy; Kristel Van Laethem | Zendy; Anne–Mieke Vandamme | Zendy; Clifford Leen | Zendy; Valeria Ghisetti | Zendy; David van de Vijver | Zendy; David Asboe | Zendy; Mattia Prosperi | Zendy; Simona Di Giambenedetto | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe

Author(s) -

Andrea De Luca,

David Dunn,

Maurizio Zazzi,

Ricardo Camacho,

Carlo Torti,

Iuri Fanti,

Rolf Kaiser,

Anders Sönnerborg,

Francisco M. Codoñer,

Kristel Van Laethem,

Anne–Mieke Vandamme,

Clifford Leen,

Valeria Ghisetti,

David van de Vijver,

David Asboe,

Mattia Prosperi,

Simona Di Giambenedetto

Publication year - 2013

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jit017

Subject(s) - drug resistance , antiretroviral drug , medicine , hiv drug resistance , retrospective cohort study , human immunodeficiency virus (hiv) , drug , resistance (ecology) , genotype , antiretroviral therapy , virology , demography , viral load , biology , pharmacology , microbiology and biotechnology , ecology , biochemistry , sociology , gene

HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20 323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research